Press Release – New York, NY – April 28, 2025 – Sichenzia Ross Ference Carmel LLP announced today that it represented BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXZ) (TSX: BCT) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, in an underwritten public offering of 3,066,666 units, including 399,999 units sold upon the full exercise of the underwriter’s option to purchase additional units. Each unit is being sold to the public at a price of $4.50 per unit for gross proceeds of approximately $13.8 million, before deducting underwriting discounts and offering expenses.
The SRFC team was led by partners Gregory Sichenzia , Avital Perlman and Jeff Cahlon, and associates Christian Lichtenberger and Benasz Hansotia.
